Engineered Bacterial Cells & Gut Microbiota for The Treatment of Type 2 Diabetes
DOI:
https://doi.org/10.61173/y2ztxr86Keywords:
Gut Microbiota, Type 2 Diabetes, Engineered Bacterial Cells, LifestyleAbstract
Type 2 diabetes (T2D) is one of the fastest-growing metabolic diseases in the world. In 2021, about 482.94 billion individuals were diagnosed with T2D, with a 10.5 % diabetes prevalence. In 2045, it is projected to have 704.9 million individuals with Type 2 Diabetes. Many clinical studies have found metabolic disorders and chronic inflammatory states in patients with type 2 diabetes, accompanied by intestinal microbiome disturbances. Gut microbiota plays an essential role in metabolism and immune regulation. Therefore, gut microbiota can be a new target for creating treatments and therapies for type 2 diabetes and related diseases. In this review, we will highlight the glucagon-like peptide-1 treatment, the Humulin treatment, and how a healthy lifestyle can control T2D.
References
[1] Xu F, Wang KY, Wang N, Li G, Liu D (2017) Modified human glucagon-like peptide-1 (GLP-1) produced in E. coli has a longacting therapeutic effect in type 2 diabetic mice. PLoS ONE 12(7): e0181939. https://doi.org/10.1371/ journal.pone.0181939
[2] HolstJ.J.(2007).Thephysiologyofglucagon-likepeptide1. Physiologicalreviews, 87(4),1409–1439. https://doi.org/10.1152/ physrev.00034.2006
[3] Patrick E. MacDonald, Wasim El-kholy, Michael J. Riedel, Anne Marie F. Salapatek, Peter E. Light, Michael B. Wheeler; The Multiple Actions of GLP-1 on the Process of Glucose-Stimulated Insulin Secretion . Diabetes1 December 2002; 51 (suppl_3): S434–S442. https://doi. org/10.2337/diabetes.51.2007.S434
[4] Suzuki, A., Nakauchi, H., & Taniguchi, H. (2003). Glucagonlike peptide 1 (1-37) converts intestinal epithelial cells into insulin-producing cells. Proceedings of the National Academy of Sciences of the United States of America, 100(9), 5034–5039. https://doi.org/10.1073/pnas.0936260100
[5] Duan FF, Liu JH, March JC. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulinsecreting cells for the treatment of diabetes. Diabetes. 2015 May;64(5):1794-803. doi: 10.2337/db14-
[635] Epub 2015 Jan 27. PMID: 25626737; PMCID: PMC4407861.
[6] HolstJ.J.(2007).Thephysiologyofglucagon-likepeptide1.Ph ysiologicalreviews,87(4),1409–1439. https://doi.org/10.1152/ physrev.00034.2006
[7] Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S.
[2014] . Adverse Effects of GLP-1 Receptor Agonists. The review of diabetic studies : RDS, 11(3-4), 202–230. https:// doi.org/10.1900/RDS.2014.11.202
[8] Joakim Nilsson, Per Jonasson, Elisabet Samuelsson, Stefan Stahl, Mathias Uhlén, Integrated production of human insulin Dean&Francis and its C-peptide, Journal of Biotechnology, Volume 48, Issue 3, 1996, Pages 241-250, ISSN 0168- 1656, https://doi.org/10.1016/0168-1656(96)01514-3.
[9] Baeshen, N.A., Baeshen, M.N., Sheikh, A. et al. Cell factories for insulin production. Microb Cell Fact 13, 141 (2014). https:// doi.org/10.1186/s12934-014-0141-0
[10] TomBlundell,GuyDodson,DorothyHodgkin,DanMercola,Ins ulin:TheStructureintheCrystaland its Reflection in Chemistry and Biology by, Editor(s): C.B. Anfinsen, John T. Edsall, Frederic M. Richards, Advances in Protein Chemistry, Academic Press, Volume 26, 1972, Pages 279-402, ISSN 0065-3233, ISBN9780120342266, https://doi. org/10.1016/S0065-3233(08)60143-6.
[11] Markussen J, Damgaard U, Diers I, Fiil N, Hansen MT, Larsen P, Norris F, Norris K, Schou O, Snel L, Thim L, Voigt HO. Biosynthesis of human insulin in yeast via single chain precursors. Diabetologia. 1986;29:568A– 569A.
[12] GoodRx. (n.d.). Humulin N (human insulin). Retrieved from goodrx: https://www.goodrx.com/humulin-n/what- is 1 3 . MayoClinic. “Type2Diabetes - S y m p t o m s a n d Causes.”MayoClinic, Mayo Clinic,20 Jan. 2021, www. mayoclinic.org/diseases-conditions/type-2-diabetes/symptomscauses/syc-20351193.
[14] CentersforDiseaseControlandPrevention.“Type2Diabetes.”C DC,30May2019, www.cdc.gov/diabetes/basics/type2.html.
[15] NIDDK. “Diabetes Diet, Eating, & Physical Activity | NIDDK.” National Institute of Diabetes and Digestive and Kidney Diseases, 16 Jan. 2019, www.niddk.nih.gov/healthinformation/diabetes/overview/diet-eating- physical-activity.
[16] CDC. “National Diabetes Statistics Report.” Center for Disease Control and Prevention, 2019, www.cdc.gov/diabetes/ data/statistics-report/index.html.
[17] medicalnewstoday. (2021, March 22). Humulin N for diabetes. Retrieved from medicalnewstoday: https://www.medicalnewstoday.com/articles/drugs-humulin-nfor-diabetes
[18] Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018; 24: 1532-1535
[19] Federation, I. D. (2021). IDF Diabetes Atlas 10th Edition. Global: International Diabetes Federation.
[20] biospectrumindia. (2007, Nov 06). 25years of Humulin, the first genetically engineered drug approved by the FDA. Retrieved from biospectrumindia.com: https://www.biospectrumindia. com/news/73/8441/25years-of-humulin- the-first-geneticallyengineered-drug-approved-by-the-fda.html
[21] Janette V. Pham1,2, Mariamawit A. Yilma1,2, Adriana Feliz1,2, Murtadha T. Majid1,2, Nicholas Maffetone1,2, Jorge R. Walker1,2, Eunji Kim3, Hyo Je Cho4, Jared M. Reynolds1,2, Myoung Chong Song3, Sung Ryeol Park1,2,5* and Yeo Joon Yoon3*. (2019, June 20). A Review of the Microbial Production of Bioactive Natural Products and Biologics. Frontiers In Microbiology, p. Artcle 1404. Whang A Nagpal R Yadav H. (2019). Bi-directional drugmicrobiome interactions of anti-diabetics. EBioMedicine., pp. 39: 591-602. Maier L et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018; 555: 623-628
[22] The discovery of insulin. China Encyclopedia. 2017
[23] Brewer, A., & Werner, C. (2020, March 23). What Are GLP- 1 Receptor Agonists and How Do They Treat Type 2 Diabetes? Healthline. https://www.healthline.com/health/type-2-diabetes/ glp-1-receptor-agoniststreatment
[24] Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S.
[2014] . Adverse Effects of GLP-1 Receptor Agonists. The review of diabetic studies : RDS, 11(3-4), 202–230. https:// doi.org/10.1900/RDS.2014.11.202
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
